Welcome to our dedicated page for SRX Health Solutions SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions entered into a private placement Securities Purchase Agreement for up to 10,000 shares of Series B convertible preferred stock and accompanying warrants, for an aggregate purchase price of up to $8.0 million in one or more closings.
At the initial closing on March 16, 2026, investors purchased 5,660 Series B shares and 22,237,666 warrants for cash proceeds of approximately $4.528 million. Each Series B share has a stated value of $1,000, ranks senior to common stock (pari passu with Series A), and is convertible at a fixed price of $0.3182 per common share, subject to adjustments.
After stockholder approval, holders may elect alternative conversion prices tied to recent volume-weighted average prices, and the company may redeem all outstanding Series B at 125% of a defined conversion amount. The company agreed to register for resale common shares issuable upon conversion of the Series B and exercise of the warrants under a registration rights agreement.
SRx Health Solutions, Inc. files a prospectus supplement registering the resale of up to 187,552,665 shares of Common Stock by existing selling stockholders. The resale stock consists of multiple tranches including warrants, convertible-preferred-related shares, exchangeable Canadian shares, private placement shares, service‑provider shares and shares issued in a share exchange, and is offered by selling stockholders subject to applicable lock-up, vesting, beneficial ownership and stock exchange limitations described herein. The supplement attaches a Form 8-K describing a limited waiver and consent permitting a new preferred‑stock offering and related waivers among existing investors.
SRx Health Solutions, Inc. registers up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC.
The prospectus supplement states these shares are outstanding or issuable under a Common Share Purchase Agreement and that the Company will not receive proceeds from any resales by the selling stockholder; the Company may, at its discretion, sell shares to Keystone under the Purchase Agreement.
SRx Health Solutions, Inc. entered into limited waiver and consent agreements with certain existing investors to support a planned new financing. The company intends to sell a new series of convertible preferred stock, called Series B Preferred Stock, together with related warrants, to new accredited investors.
Under these waivers, existing note and Series A preferred investors agree to permit this new offering and give up their contractual rights to participate in it and in any later similar financings. Required holders of Series A Preferred Stock also consent so that the new Series B Preferred Stock may rank on an equal footing with the Series A Preferred Stock for dividends, distributions, and liquidation payments.
The filing also reminds investors that SRx previously raised capital through senior secured convertible notes with an original principal amount of $7.65 million and through a Series A preferred stock financing that generated approximately $15.23 million in proceeds along with related warrants.
SRx Health Solutions, Inc. files a prospectus supplement registering up to 187,552,665 shares of common stock for resale by named selling stockholders, consisting of PIPE‑related warrants and conversions, exchangeable shares, private placement shares, service provider shares and shares issued in a share exchange.
The resale is by the Selling Stockholders or their permitted transferees from time to time, subject to lock-up, vesting, beneficial‑ownership and exchange limitations described in the prospectus supplement. The supplement incorporates the Company’s Form 10‑Q for the quarter ended December 31, 2025, which discloses continuing operations (consumer pet products), discontinued SRx Canada operations, a net loss of $8.614 million for the quarter, and digital assets of $7.996 million at fair value as of December 31, 2025.
SRx Health Solutions, Inc. files a prospectus supplement registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC, including shares outstanding or issuable under a Common Share Purchase Agreement.
The prospectus states the company will not receive proceeds from any resales by the selling stockholder; the company may, at its discretion, sell shares to Keystone under the ELOC Purchase Agreement and would receive proceeds if it does so. The filing incorporates the Company’s Form 10-Q for the quarter ended December 31, 2025 and discloses 298,207,684 shares outstanding as of February 11, 2026.
SRx Health Solutions, Inc. files a prospectus supplement to register up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC. The registration covers resale only; the Company will not receive proceeds from sales by the Selling Stockholder, though it may receive proceeds if it sells shares to Keystone under the ELOC Purchase Agreement.
The supplement also attaches an 8-K disclosing that the NYSE American issued a public warning for failures to comply with Sections 301 and 713 after the Company issued approximately 7.5 million shares upon conversion of Series A preferred stock; all Preferred Shares have been converted or redeemed.
SRx Health Solutions, Inc. registered for resale up to 187,552,665 shares of common stock under a prospectus supplement dated February 26, 2026. The resale pool includes shares issuable on conversion or exercise from prior PIPE financings, exchangeable Canadian shares, private placement shares, service provider shares, and shares issued in a share exchange.
The company also reported receipt of a public Warning Letter from NYSE Regulation dated February 18, 2026, citing failures to obtain exchange listing approval and adequate shareholder approval related to approximately 7.5 million common shares issued upon conversion of Series A Convertible Preferred Stock. As of the report, all Preferred Shares have been converted or redeemed and no Preferred Shares remain outstanding.
SRx Health Solutions, Inc. reported receiving a public Warning Letter from NYSE American, indicating it failed to comply with Sections 301 and 713 of the exchange’s Company Guide. The issue stems from issuing approximately 7.5 million common shares upon conversion of Series A preferred stock between December 31, 2025 and January 23, 2026.
NYSE Regulation states the company did not obtain prior listing approval for these additional shares and did not secure sufficient shareholder approval for an issuance exceeding 20% of common stock outstanding. The exchange notes that future failures to meet listing requirements could lead to further action, including potential delisting proceedings. SRx Health says all Series A preferred shares have now been converted or redeemed, with none outstanding.
SRx Health Solutions, Inc. reported receiving a public Warning Letter from NYSE American, indicating it failed to comply with Sections 301 and 713 of the exchange’s Company Guide. The issue stems from issuing approximately 7.5 million common shares upon conversion of Series A preferred stock between December 31, 2025 and January 23, 2026.
NYSE Regulation states the company did not obtain prior listing approval for these additional shares and did not secure sufficient shareholder approval for an issuance exceeding 20% of common stock outstanding. The exchange notes that future failures to meet listing requirements could lead to further action, including potential delisting proceedings. SRx Health says all Series A preferred shares have now been converted or redeemed, with none outstanding.
SRx Health Solutions Inc. reported net sales of $2.8 million and a net loss of $8.6 million for the quarter ended December 31, 2025, as it refocuses on its Halo premium pet food business after exiting its Canadian healthcare operations.
Gross profit was $1.1 million on cost of goods sold of $1.8 million, but heavy selling, general and administrative expenses of $4.8 million and interest and other expenses, including a $3.1 million loss on extinguishment of debt and a $0.5 million loss on digital assets, drove the loss. Cash rose to $13.1 million, helped by new equity and preferred stock financings, while convertible debt totaled $21.0 million. The company also invested $8.5 million into crypto assets and subsequently raised about $29.1 million through its equity line, significantly increasing shares outstanding to 298.2 million as of February 11, 2026.